表紙
市場調査レポート

眼科用医薬品市場の予測 2015-2025年:ドライアイ、緑内障、網膜疾患、アレルギー、炎症および感染症治療薬における主要企業の展望

Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs

発行 Visiongain Ltd 商品コード 239210
出版日 ページ情報 英文 337 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
眼科用医薬品市場の予測 2015-2025年:ドライアイ、緑内障、網膜疾患、アレルギー、炎症および感染症治療薬における主要企業の展望 Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs
出版日: 2015年07月03日 ページ情報: 英文 337 Pages
概要

眼科用医薬品の需要増加、医療保険の拡大、R&Dパイプラインの強さ、およびドラッグデリバリー技術の発展は、眼科用医薬品の売り上げ増加に大きく貢献すると予測されています。

当レポートでは、世界の眼科用医薬品の市場について調査し、主な眼疾患区分別の収益予測、現在の主要薬剤、主要薬剤の収益および市場シェア予測、パイプラインの動向、主要12カ国の国別分析、市場影響因子の分析、業界の専門家へのインタビュー、主要企業のプロファイルなどを詳細にわたってまとめています。

第1章 レポート概要

第2章 イントロダクション:眼科用医薬品

  • 医薬品産業の概要
  • 眼の構造と機能
  • 眼の疾患による世界の医療費負担
  • 眼科用医薬品:市場区分
  • 緑内障:失明の主要な原因
  • 加齢性黄斑変性症 (AMD)
  • 糖尿病性網膜症 (DR)
  • 眼科アレルギー・アレルギー性結膜炎
  • 眼科炎症性疾患
  • 眼科感染症
  • ドライアイ症候群
  • 臨床試験のフェーズ
  • 眼科用医薬品:本レポートの市場定義

第3章 世界の眼科用医薬品市場

  • 世界の眼科用医薬品市場:市場概要
  • 世界の眼科用医薬品市場の分類
  • 世界の眼科用医薬品市場
  • 世界の眼科用医薬品市場:市場予測
  • 眼科用医薬品:市場シェアの推移、部門別

第4章 網膜疾患治療薬市場:市場分析・予測

  • 網膜疾患治療薬市場における主要製品
  • 網膜疾患:市場動向・発展
  • 網膜疾患治療薬:市場予測
  • 網膜疾患治療の主な医薬品
  • Lucentis (ranibizumab) Roche/Novartis
  • Eylea (aflibercept) Regeneron/Bayer/参天製薬)
  • Avastin (bevacizumab) Roche
  • Visudyne (verteporfin) Valeant/Novartis
  • Jetrea (ocriplasmin) ThromboGenics/Novartis
  • その他

第5章 眼科アレルギー、炎症および感染症治療薬市場:市場分析・予測

  • 主要製品
  • 市場予測
  • 主な医薬品
  • Patanol・Pataday (olopatadine) - Alcon (Novartis)
  • Vigamox (moxifloxacin) - Alcon (Novartis)
  • TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
  • Bromday (bromfenac) - Valeant
  • Cravit (levofloxacin) - 参天製薬
  • Acular (ketorolac) - Allergan (Actavis)
  • AzaSite (azithromycin) - Akorn
  • その他の眼科アレルギー、炎症および感染症治療薬:売上予測

第6章 緑内障治療薬の市場

  • 緑内障治療薬:市場概要
  • 緑内障治療薬:市場動向・発展
  • 緑内障治療薬:市場予測
  • 主な緑内障治療薬
  • Lumigan・Ganfort - Allergan (Actavis)
  • Xalatan・Xalacom (latanoprost) - Pfizer
  • Travatan/Travatan Z・DuoTrav (travoprost, Novartis)
  • Alphagan/Alphagan P・Combigan (brimonidine) - Allergan
  • Trusopt・Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
  • Azopt (brinzolamide) - Novartis
  • Tapros (tafluprost) 参天製薬
  • Zioptan (tafluprost) - Akorn
  • その他

第7章 ドライアイ治療薬市場:市場分析・予測

  • ドライアイ治療薬:市場概要
  • ドライアイ治療薬:市場動向・発展
  • 主要薬剤
  • 市場予測
  • 主要薬剤の市場シェア
  • トレンド・開発動向
  • Restasis (ciclosporin, Allergan)
  • Refresh Brand Products (Allergan)
  • Hyalein (hyaluronic acid) 参天製薬
  • Diquas (diaquafosol) 参天製薬
  • その他

第8章 眼科治療薬の主要国市場

  • 眼科治療薬市場:地域別
  • 主要国市場:予測
  • 地域の眼科治療薬市場:分析・予測
  • 米国:最大の眼科治療薬市場
  • EU5カ国
  • 日本
  • 中国
  • ブラジル
  • ロシア
  • インド
  • メキシコ
  • その他

第9章 眼科治療薬市場の主要企業

  • 眼科治療薬:変化する市場情勢
  • Novartis (Alcon)
  • Allergan (Actavis)
  • Roche
  • 参天製薬
  • Regeneron
  • Valeant
  • Pfizer
  • Bayer
  • 千寿製薬

第10章 眼科治療薬:R&Dパイプライン

  • 眼科治療薬のパイプライン:網膜疾患における集中的な開発の取り組み
  • 網膜疾患治療薬:開発パイプライン
  • 眼科アレルギー、炎症および感染症治療薬の状況:開発パイプライン
  • 緑内障の治療薬:開発パイプライン
  • ドライアイ治療薬:開発パイプライン
  • その他の開発中の眼疾患治療薬

第11章 眼科治療薬市場の定性分析

  • 眼科治療薬の市場影響因子
  • 世界の眼科治療薬市場のSWOT分析
  • ポーターのファイブフォース分析

第12章 専門家の見解

第13章 結論

  • 現在の市場・市場予測の概要
  • 眼科治療薬における主な部門
  • 眼科治療薬市場における主な地域
  • 眼科治療薬市場における主な企業
  • 眼科治療薬に将来待ち受けていること

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0054

Ophthalmic drugs - new study showing you trends, partnerships, and predicted revenues

Where is the market for ophthalmic drugs heading? What are the commercial prospects for this market? Visiongain's new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Our 337 page report provides 243 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess:

  • Forecasted sales at world market, submarket, regional and national level
  • You will see financial results and revenue predictions
  • Interviews, trends, opportunities

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find:

  • Original analyses, with business outlooks and developments
  • Discover qualitative analyses (including SWOT and Porter's Five Forces)
  • Company profiles and commercial developments

Read the full transcript of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr Patrik De Haes, CEO, ThromboGenics nv
  • Mr Wouter Piepers, Global Head of Corporate Communications & Investor Relations, ThromboGenics nv
  • A spokesperson for Akorn Pharmaceuticals

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of five world-level submarkets to 2025:

  • Glaucoma drugs market forecast 2015-2025
  • Dry eye drugs market forecast 2015-2025
  • Allergic, inflammatory and infective drugs market forecast 2015-2025
  • Retinal disorder drugs market forecast 2015-2025
  • Other ophthalmic drugs market forecast 2015-2025

Our investigation shows business research and analysis with individual revenue forecasts and discussions for each submarket.

See revenue forecasts for products

How will leading drugs perform to 2025 at world level? Our study forecasts sales of 27 marketed drugs, including these brands:

  • Lucentis
  • Eylea
  • Restasis
  • Vigamox
  • Pataday/ Patanol
  • Jetrea
  • Lumigan and Ganfort
  • Xalatan/Xalacom
  • Zioptan
  • Cravit

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?

You will discover individual revenue forecasts for 12 leading national markets to 2025. There are many commercial opportunities to exploit in both developed and developing countries.

  • US
  • China
  • Japan
  • Germany
  • India
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • Mexico
  • Rest of the World

Our analyses show that emerging economies, particularly in South America and Asia, will continue to achieve high revenue growth to 2025. Various economic, geographical, and regulatory factors globally will influence the market.

Leading companies and potential for market growth

We expect the rising demand for ophthalmic drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies to contribute to a significant increase in sales for ophthalmic drugs to 2025.

Our work shows you what organisations hold greatest potential. See profiles of 9 leading companies, including these:

  • Pfizer
  • Santen
  • Bayer
  • Senju
  • Regeneron
  • Novartis (Alcon)
  • Allergan (Actavis)
  • Roche
  • Valeant (including Bausch & Lomb)

A company profile gives you the following information:

  • Revenue forecast for ophthalmic drugs from 2015 to 2025
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), and collaborations, including alliances, partnerships, and joint ventures
  • Discussion of a company's activities and outlook
  • Ophthalmic drugs revenue forecast from 2015 to 2025

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will regulatory changes have?

Research and development activities - assess innovation, trends and possibilities

What is happening in the R&D pipeline for ophthalmic treatments? You see developmental trends, gaining insight into each phase of the ophthalmology R&D pipeline for:

  • Dry eye drugs
  • Glaucoma drugs
  • Allergic, infective and inflammatory drugs
  • Retinal disorder drugs
  • Other progress in ophthalmology

Our study also discusses these agents and technologies, among others:

  • Gene therapy
  • Oral drug candidates
  • Drug delivery
  • Novel small molecules

What issues will affect the ophthalmic drugs market?

Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting ophthalmic treatments. You will find discussions, including qualitative analyses:

  • A strong R&D pipeline
  • Patent expiries and generic competition
  • Patient compliance and the advances in topical drug delivery
  • Pricing and reimbursement pressures created by government cost-cutting initiatives
  • Growth areas in dry eye and retinal disorders
  • The changing socio-economic conditions impacting ophthalmic drug demand

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape

How the Ophthalmic Drugs Market Forecast 2015-2025: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs report helps you

In summary our 337 page report gives you the following knowledge:

  • Revenues to 2025 for the overall ophthalmic drugs market - discover the industry's prospects, finding promising areas for investments and revenues
  • Revenue forecasts to 2025 for four product categories (therapeutic classes) within ophthalmic drugs - discover forecasts for Dry eye drugs, Retinal disorders drugs, Glaucoma drugs, Allergic, inflammatory and infective drugs, and Other ophthalmic drugs
  • Revenue forecast to 2025 for 12 leading national markets - US, China, Japan, India, Germany, France, UK, Italy, Spain, Russia, Brazil, Mexico, and Rest of the World
  • Assess leading companies - hear about the products, results and strategies, including recent activities, future outlook, and ophthalmic drugs revenue forecast for 9 leading companies, including Pfizer, Novartis, Roche, Regeneron, Senju, Bayer, Santen, Valeant, and Allergan
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • Opinions from our survey, seeing interviews with industry authorities
  • IP protection and generic drug competition - see what affects product revenue

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and the leading companies within it. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Ophthalmic Drugs: Market Overview
  • 1.2. Global Ophthalmic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. An Introduction To Ophthalmic Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
  • 2.1.1. Ophthalmic Treatments - An Industry Overview
  • 2.2. The Human Eyes - Structurally Delicate And Functionally Intricate Organs
  • 2.3. The Global Burden Of Eye Disease
  • 2.4. Ophthalmic Drugs: Market Segmentation
  • 2.5. Glaucoma: A Major Cause Of Vision Loss
    • 2.5.1. A Classification Of Glaucoma
      • 2.5.1.1. Primary Open-Angle Glaucoma
      • 2.5.1.2. Acute Angle-Closure Glaucoma
      • 2.5.1.3. Congenital Glaucoma
      • 2.5.1.4. Secondary Glaucoma
      • 2.5.1.5. Normal-Tension Glaucoma
      • 2.5.1.6. Ocular Hypertension
    • 2.5.2. Risk Factors For Glaucoma
    • 2.5.3. Diagnosis Of Glaucoma
    • 2.5.4. Drug Treatment Of Glaucoma
    • 2.5.5. Laser Treatment And Surgery For Glaucoma
  • 2.6. Age-Related Macular Degeneration (AMD)
    • 2.6.1. Dry (non-exudative) AMD
    • 2.6.2. Wet (exudative) AMD
    • 2.6.3. Risk Factors For AMD
    • 2.6.4. Diagnosis of AMD
    • 2.6.5. Treatment of AMD
  • 2.7. Diabetic Retinopathy (DR)
    • 2.7.1. Diagnosis Of Diabetic Retinopathy
    • 2.7.2. Treatment Of Diabetic Retinopathy
  • 2.8. Ocular Allergy And Allergic Conjunctivitis
    • 2.8.1. Diagnosis Of Ocular Allergy
    • 2.8.2. Treatment Of Ocular Allergy
  • 2.9. Ocular Inflammatory Disease
    • 2.9.1. Treatment Of Ocular Inflammatory Disease
  • 2.10. Eye Infections
    • 2.10.1. Treatment Of Eye Infections
  • 2.11. Dry Eye Syndrome
    • 2.11.1. Treatment of Dry Eye Syndrome
  • 2.12. Phases of Clinical Trials
  • 2.13. Ophthalmic Drugs: Market Definition In This Report

3. The Global Ophthalmic Drugs Market, 2015-2025

  • 3.1. The Global Ophthalmic Drugs Market: Market Overview
  • 3.2. Categorisation Of The Global Ophthalmic Drugs Market
  • 3.3. The Global Ophthalmic Drugs Market In 2014
  • 3.4. The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 3.5. Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025

4. The Retinal Disorder Drugs Market: Market Analysis And Forecast 2015-2025

  • 4.1. Leading Products In The Retinal Disorder Drugs Market, 2014
  • 4.2. Retinal Disorders: Market Trends And Developments, 2015
    • 4.2.1. The Rise And Rise Of Lucentis
    • 4.2.2. The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
    • 4.2.3. How Likely Is Avastin's Expansion Into Age-Related Macular Degeneration?
    • 4.2.4. Jetrea: Underwhelming Sales And ThromboGenics' Efforts To Reverse It
    • 4.2.5. Drug/Device Combination Products Entering The Market
    • 4.2.6. Does Regenerative Medicine Have A Successful Future In Ophthalmics?
  • 4.3. Retinal Disorder Drugs: Market Forecast 2015-2025
    • 4.3.1. Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 4.4. Leading Drugs For The Treatment Of Retinal Disorders
  • 4.5. Lucentis (ranibizumab) - Roche/ Novartis
    • 4.5.1. Lucentis: Sales Forecast 2015-2025
    • 4.5.2. Less Frequent Dosing Approved In US For Lucentis
    • 4.5.3. New Indications For Lucentis
    • 4.5.4. Possible Combination Therapy Involving Lucentis
  • 4.6. Eylea (aflibercept) - Regeneron/ Bayer/ Santen
    • 4.6.1. Recent Approvals For Eylea
    • 4.6.2. Eylea: Sales Forecast 2015-2025
    • 4.6.3. Possible Combination Therapies Involving Eylea
  • 4.7. Avastin (bevacizumab) - Roche
    • 4.7.1. Avastin: Sales Forecast 2015-2025
    • 4.7.2. Compounding Pharmacies And Safety Risks
  • 4.8. Visudyne (verteporfin) - Valeant/ Novartis
    • 4.8.1. Visudyne: Sales Forecast 2015-2025
  • 4.9. Jetrea (ocriplasmin) - ThromboGenics/ Novartis
    • 4.9.1. Jetrea: Recent Sales Performance
    • 4.9.2. Clinical Study Plans For Jetrea
    • 4.9.3. Jetrea: Sales Forecast 2015-2025
    • 4.9.4. Possible Acquisition Move On ThromboGenics
    • 4.9.5. R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
  • 4.10. Other Retinal Disorder Drugs
    • 4.10.1. Iluvien (fluocinolone implant) - Alimera Sciences
    • 4.10.2. Ozurdex (dexamethasone implant) - Allergan
    • 4.10.3. Other Retinal Disorder Drugs: Sales Forecast 2015-2025

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2015-2025

  • 5.1. Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
    • 5.1.1. Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
    • 5.1.2. The Growth Prospects For Allergic, Inflammatory And Infective Drugs
    • 5.1.3. Topical NSAIDs Launched: Prolensa and Ilevro
  • 5.2. Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
    • 5.2.1. Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 5.3. Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
  • 5.4. Patanol And Pataday (olopatadine) - Alcon (Novartis)
    • 5.4.1. Pataday: Sales Forecast 2015-2025
    • 5.4.2. Impending Generic Competition For Patanol And Pataday
    • 5.4.3. Approval Of Pazeo Solution
    • 5.4.4. Patanol: Sales Forecast 2015-2025
  • 5.5. Vigamox (moxifloxacin) - Alcon (Novartis)
    • 5.5.1. Intensifying Competition And Generics Drug Challenge To Vigamox
    • 5.5.2. Moxeza: A Next-Generation Form of Vigamox
    • 5.5.3. Vigamox: Sales Forecast 2015-2025
  • 5.6. TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
    • 5.6.1. The Development And Commercialisation Of TobraDex ST
    • 5.6.2. TobraDex: Sales Forecast 2015-2025
  • 5.7. Bromday (bromfenac) - Valeant
    • 5.7.1. Prolensa: A New Formulation Of Bromfenac
    • 5.7.2. Competition From Ilevro/Nevanac
    • 5.7.3. Bromday: Sales Forecast 2015-2025
  • 5.8. Cravit (levofloxacin) - Santen
    • 5.8.1. Cravit: Sales Forecast 2015-2025
  • 5.9. Acular (ketorolac) - Allergan (Actavis)
    • 5.9.1. Acular: Sales Forecast 2015-2025
  • 5.10. AzaSite (azithromycin) - Akorn
    • 5.10.1. AzaSite: Sales Forecast 2015-2025
  • 5.11. Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025

6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-2025

  • 6.1. Glaucoma Drugs: Market Overview
    • 6.1.1. Leading Products In The Glaucoma Drugs Market, 2014
  • 6.2. Glaucoma Drugs: Market Trends And Developments, 2015
    • 6.2.1. Patent Expiration: A Major Restraint For Glaucoma Drugs
    • 6.2.2. Preservative-Free Formulation Trends
    • 6.2.3. Innovation In Treatments For Glaucoma
    • 6.2.4. Simbrinza: First Beta-Blocker-Free Combination
  • 6.3. Glaucoma Drugs: Market Forecast 2015-2025
    • 6.3.1. Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 6.4. Leading Drugs For The Treatment Of Glaucoma
  • 6.5. Lumigan And Ganfort (bimatoprost) - Allergan (Actavis)
    • 6.5.1. Lumigan And Ganfort: Sales Forecast 2015-2025
  • 6.6. Xalatan And Xalacom (latanoprost) - Pfizer
    • 6.6.1. Xalatan/Xalacom: Sales Forecast 2015-2025
  • 6.7. Travatan/Travatan Z And DuoTrav (travoprost) - Novartis
    • 6.7.1. Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
  • 6.8. Alphagan/Alphagan P And Combigan (brimonidine) - Allergan
    • 6.8.1. Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
  • 6.9. Trusopt And Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
    • 6.9.1. Divestment Agreement With Santen And Akorn
    • 6.9.2. Trusopt: Sales Forecast 2015-2025
    • 6.9.3. Cosopt And Cosopt PF: Sales Forecast 2015-2025
  • 6.10. Azopt (brinzolamide) - Novartis
    • 6.10.1. Azopt: Sales Forecast 2015-2025
  • 6.11. Tapros (tafluprost) - Santen
    • 6.11.1. Tapros: Sales Forecast 2015-2025
  • 6.12. Zioptan (tafluprost) - Akorn
    • 6.12.1. Zioptan: Sales Forecast 2015-2025
  • 6.13. Other Glaucoma Drugs: Sales Forecast 2015-2025

7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025

  • 7.1. Dry Eye Drugs: Market Overview
    • 7.1.1. Leading Products In The Dry Eye Drugs Market, 2014
  • 7.2. Dry Eye Drugs: Market Trends And Developments, 2015
    • 7.2.1. Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
    • 7.2.2. Intensifying Research Focused On Dry Eye
    • 7.2.3. Improving Diagnostic Tools
  • 7.3. Dry Eye Drugs: Market Forecast 2015-2025
    • 7.3.1. Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
  • 7.4. Leading Drugs For The Treatment Of Dry Eye
  • 7.5. Restasis (ciclosporin) - Allergan (Actavis)
    • 7.5.1. Restasis Patent Elongation
    • 7.5.2. Restasis: Sales Forecast 2015-2025
  • 7.6. Refresh Brand Products - Allergan (Actavis)
    • 7.6.1. Refresh Brand Products: Sales Forecast 2015-2025
  • 7.7. Hyalein (hyaluronic acid) - Santen
    • 7.7.1. Hyalein: Sales Forecast 2015-2025
  • 7.8. Diquas (diaquafosol) - Santen
    • 7.8.1. Diquas: Sales Forecast 2015-2025
  • 7.9. Other Dry Eye Drugs: Sales Forecast 2015-2025
  • 7.10. Other Ophthalmic Drugs
    • 7.10.1. Hetlioz (tasimelteon) - Vanda Pharmaceuticals
      • 7.10.1.1. Hetlioz: Sales Forecast 2015-2025

8. Leading National Markets For Ophthalmic Drugs, 2015-2025

  • 8.1. The Ophthalmic Drugs Market By Region
    • 8.1.1. The Global Distribution Of Ophthalmic Drugs In 2014
  • 8.2. Leading National Markets: Forecast 2015-2025
    • 8.2.1. Changing Market Shares By Region, 2015-2025
  • 8.3. Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
  • 8.4. United States: The Largest Ophthalmic Drugs Market
    • 8.4.1. How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
    • 8.4.2. US Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.5. EU5
    • 8.5.1. EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
      • 8.5.1.1. EU5 Markets: Changing Market Shares By Country, 2015-2025
    • 8.5.2. Germany
      • 8.5.2.1. German Ophthalmic Drugs Market: Market Forecast 2015-2025
    • 8.5.3. France
      • 8.5.3.1. French Ophthalmic Drugs Market: Market Forecast 2015-2025
    • 8.5.4. UK
      • 8.5.4.1. UK Ophthalmic Drugs Market: Market Forecast 2015-2025
    • 8.5.5. Italy
      • 8.5.5.1. Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
    • 8.5.6. Spain
      • 8.5.6.1. Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.6. Japan
    • 8.6.1. The Cost Of Treatment In Japan
    • 8.6.2. Japanese Pharmaceutical Industry Regulatory Reform
    • 8.6.3. Japanese Ophthalmic Drugs Market Forecast 2015-2025
  • 8.7. China
    • 8.7.1. Expansion Of Healthcare Coverage And Reimbursement In China
    • 8.7.2. Price Controls And The Anhui Model
    • 8.7.3. Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.8. Brazil
    • 8.8.1. How Will Brazil's Growing Healthcare Influence Ophthalmic Drugs
    • 8.8.2. Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.9. Russia
    • 8.9.1. How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.9.2. Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.10. India
    • 8.10.1. The Impact Of The Drug Prices Control Order On Indian Pharma
    • 8.10.2. India's Expansion Of Healthcare Provision
    • 8.10.3. Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.11. Mexico
    • 8.11.1. Mexican Healthcare Reform: Introducing Seguro Popular
    • 8.11.2. Are Multinationals Waking Up To Mexico's Market Potential?
    • 8.11.3. Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
  • 8.12. Rest of the World
    • 8.12.1. Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025

9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025

  • 9.1. Ophthalmic Drugs - A Changing Market Landscape
    • 9.1.1. Leading Companies In The Ophthalmic Drugs Market, 2015
    • 9.1.2. Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
    • 9.1.3. Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
  • 9.2. Novartis (Alcon)
    • 9.2.1. Novartis: Ophthalmic Drugs Portfolio, 2015
    • 9.2.2. Novartis: Sales Forecast 2015-2025
    • 9.2.3. Novartis: Ophthalmic Drugs Development Pipeline, 2015
    • 9.2.4. Novartis: Recent Developments
      • 9.2.4.1. Novartis Restructures Following Strategic Review
      • 9.2.4.2. Novartis Licenses Ophthotech's Fovista
  • 9.3. Allergan (Actavis)
    • 9.3.1. Allergan: Ophthalmic Drugs Portfolio
    • 9.3.2. Allergan: Recent Developments
      • 9.3.2.1. Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
      • 9.3.2.2. How Real Is The Threat Of Generic Restasis?
      • 9.3.2.3. Valeant's Attempted Takeover Squashed By Actavis Bid
    • 9.3.3. Allergan: Sales Forecast 2015-2025
    • 9.3.4. Allergan: Ophthalmic Drugs Development Pipeline, 2015
  • 9.4. Roche
    • 9.4.1. Roche: Ophthalmic Drugs Portfolio, 2015
      • 9.4.1.1. Lucentis: US Sales Forecast 2015-2025
    • 9.4.2. Roche: Sales Forecast 2015-2025
    • 9.4.3. Roche: Ophthalmic Drugs Development Pipeline, 2015
  • 9.5. Santen
    • 9.5.1. Santen: Ophthalmic Drugs Portfolio, 2015
    • 9.5.2. Santen: Recent Developments
      • 9.5.2.1. Santen Acquires Novagali Pharma
      • 9.5.2.2. Santen Acquires Merck's Ophthalmic Drugs Portfolio
    • 9.5.3. Santen: Sales Forecast 2015-2025
    • 9.5.4. Santen: Ophthalmic Drugs Development Pipeline, 2015
  • 9.6. Regeneron
    • 9.6.1. Regeneron: Ophthalmic Drugs Portfolio, 2015
    • 9.6.2. Regeneron: Recent Developments
      • 9.6.2.1. Expanding Indications For Eylea
      • 9.6.2.2. Eylea/Zaltrap And The Davis-Smyth Patent Agreements
    • 9.6.3. Regeneron: Sales Forecast 2015-2025
    • 9.6.4. Regeneron: Ophthalmic Drugs Development Pipeline, 2015
  • 9.7. Valeant
    • 9.7.1. Valeant: Ophthalmic Drugs Portfolio, 2015
    • 9.7.2. Valeant: Recent Developments
      • 9.7.2.1. Valeant's Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
    • 9.7.3. Valeant: Sales Forecast 2015-2025
    • 9.7.4. Valeant: Ophthalmic Drugs Development Pipeline, 2015
  • 9.8. Pfizer
    • 9.8.1. Pfizer: Ophthalmic Drugs Portfolio, 2015
      • 9.8.1.1. Xalatan/Xalacom - Pfizer's Leading Ophthalmic Products
      • 9.8.1.2. Macugen - Valeant/Pfizer
    • 9.8.2. Pfizer: Recent Developments
      • 9.8.2.1. Pfizer Attempts to Acquire AstraZeneca
    • 9.8.3. Pfizer: Sales Forecast 2015-2025
    • 9.8.4. Pfizer: Ophthalmic Drugs Development Pipeline, 2015
  • 9.9. Bayer
    • 9.9.1. Bayer: Ophthalmic Drugs Portfolio
    • 9.9.2. Bayer: Sales Forecast 2015-2025
  • 9.10. Senju
    • 9.10.1. Senju: Ophthalmic Drugs Portfolio
    • 9.10.2. Senju: Sales Forecast 2015-2025
    • 9.10.3. Senju: Ophthalmic Drugs Development Pipeline, 2015
      • 9.10.3.1. Y 39983 (SNJ 1656)
      • 9.10.3.2. Difluprednate (SJE-2079)

10. Ophthalmic Drugs: Research And Development Pipeline, 2015-2025

  • 10.1. The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
  • 10.2. Drugs For Retinal Disorders: Development Pipeline, 2015
    • 10.2.1. Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
    • 10.2.2. Retinal Disorders: Filed or Recently Launched
      • 10.2.2.1. Compaq Sipp (conbercept) - Chengdu Kanghong Pharmaceutical
      • 10.2.2.2. Lipidil (fenofibrate) - Abbott
      • 10.2.2.3. Iluvien (fluocinolone) - Alimera Sciences
    • 10.2.3. Drugs In Phase 3 Development For Retinal Disorders
      • 10.2.3.1. Fovista and Zimura - Ophthotech Corporation
      • 10.2.3.2. Lampalizumab (anti-Factor D Fab) - Roche
      • 10.2.3.3. MC-1101 (hydralazine) - MacuCLEAR
      • 10.2.3.4. Tandospirone (serotonin 1A agonist) - Alcon (Novartis)
      • 10.2.3.5. UF-021 (unoprostone) - R-Tech Ueno
    • 10.2.4. Drugs In Phase 2 Development For Retinal Disorders
      • 10.2.4.1. AKB-9778 (Tie2 activator) - Aerpio Therapeutics
      • 10.2.4.2. Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
      • 10.2.4.3. AGN150998 And MP0260 (Anti-VEGF DARPins) - Allergan
      • 10.2.4.4. AGN208397 (beclomethasone) - Allergan
      • 10.2.4.5. CPC 551 - Colby Pharmaceutical
      • 10.2.4.6. Darapladib And GSK933776 - GlaxoSmithKline
      • 10.2.4.7. ESBA1008 (anti-VEGF mAb) - Alcon (Novartis)
      • 10.2.4.8. iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
      • 10.2.4.9. iSONEP (sonepcizumab) - Lpath
      • 10.2.4.10. LFG316 (anti-C5 mAb) - Novartis
      • 10.2.4.11. Novadur (Intravitreal brimonidine implant) - Allergan
      • 10.2.4.12. Optina (danazol) - Ampio Pharmaceuticals
      • 10.2.4.13. PF-655 (synthetic siRNA) - Quark/Pfizer
      • 10.2.4.14. Premiplex (protein replacement therapy) - Shire
      • 10.2.4.15. Renexus (ciliary neurotrophic factor) - Neurotech
      • 10.2.4.16. Squalamine (anti-angiogenic drug) - OHR Pharmaceutical
      • 10.2.4.17. Zybrestat (fosbretabulin) - Oxigene/Symphony VIDA
    • 10.2.5. Drugs In Phase 1 And Pre-clinical Development For Retinal Disorders
      • 10.2.5.1. BDM-E - BioDiem
      • 10.2.5.2. NADPH Oxidase Inhibitors - Alimera Sciences
      • 10.2.5.3. NS2 (aldehyde trap) - Aldeyra Therapeutics
      • 10.2.5.4. PAN-90806 (topical VEGF inhibitor) - PanOptica
      • 10.2.5.5. Plasma Kallikrein Inhibitors (KVD001) - KalVista
      • 10.2.5.6. QLT091001 (synthetic retinoid) - QLT
  • 10.3. Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2015
    • 10.3.1. Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
      • 10.3.1.1. EGP-437 (dexamethasone) - EyeGate Pharmaceuticals
      • 10.3.1.2. IBI-10090 and IBI-20089 - Icon Bioscience
      • 10.3.1.3. LE-MPP (loteprednol etabonate) - Kala
    • 10.3.2. Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
      • 10.3.2.1. CF101 (adenosine A3 receptor agonist) - Can-Fite BioPharma and OphthaliX
      • 10.3.2.2. FST-100 (povidone-iodine/dexamethasone) - ForeSight Biotherapeutics
      • 10.3.2.3. NVC-422 (auriclosene) - NovaBay
      • 10.3.2.4. Sarilumab - Regeneron
      • 10.3.2.5. V404 PDS - ForSight VISION
    • 10.3.3. Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
      • 10.3.3.1. Finafloxacin - MerLion Pharmaceuticals/Novartis
  • 10.4. Drugs For Glaucoma: Development Pipeline, 2015
    • 10.4.1. Drugs In Phase 2&3 Development For Glaucoma
      • 10.4.1.1. Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
      • 10.4.1.2. AMA0076 (ROCK inhibitor) - Amakem
      • 10.4.1.3. Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) - Aerie Pharmaceuticals
    • 10.4.2. Drugs In Phase 1 And Pre-clinical Development For Glaucoma
  • 10.5. Drugs For Dry Eye: Development Pipeline, 2015
    • 10.5.1. Drugs In Phase 3 Development For Dry Eye
      • 10.5.1.1. EBI-005 (IL-1R antagonist) - Eleven Biotherapeutics
      • 10.5.1.2. Lifitegrast (integrin antagonist) - Shire
      • 10.5.1.3. MIM-D3 (tyrosine kinase receptor antagonist) - Valeant
      • 10.5.1.4. SI-614 (modified hyaluronate) - Seikagaku
    • 10.5.2. Drugs In Phase 2 Development For Dry Eye
      • 10.5.2.1. ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
      • 10.5.2.2. Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
  • 10.6. Other Drugs In The Development Pipeline For Ophthalmic Conditions
    • 10.6.1. Brimonidine For Eye Whitening - Valeant
    • 10.6.2. GS-101 (aganirsen) - Gene Signal
    • 10.6.3. Omidria (phenylephrine/ketorolac) - Omeros

11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-2025

  • 11.1. Market Factors Influencing Ophthalmic Drugs
  • 11.2. SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
    • 11.2.1. Strengths
      • 11.2.1.1. A Healthy R&D Pipeline
      • 11.2.1.2. Advances In Drug Delivery Technologies
      • 11.2.1.3. Support For Reimbursement And Payment Approvals
      • 11.2.1.4. Gene Therapy And RNA Interference Technology
      • 11.2.1.5. New Ophthalmic Therapeutic Applications For Drugs
      • 11.2.1.6. Development Of Neuroprotective Anti-Glaucoma Medications
      • 11.2.1.7. Biomarkers As Tools For Better Diagnosis And Treatment
    • 11.2.2. Weaknesses
      • 11.2.2.1. Patient Adherence To Treatment
      • 11.2.2.2. High Treatment Burden On Patients And Healthcare Providers
      • 11.2.2.3. Under-Diagnosis And Under-Treatment
    • 11.2.3. Opportunities
      • 11.2.3.1. Sustained-Release Ocular Implants
      • 11.2.3.2. The Impact Of A Rapidly Ageing Global Population
      • 11.2.3.3. Increasing Prevalence Of Eye Diseases And Diabetes
      • 11.2.3.4. Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In Prevalence
      • 11.2.3.5. Unmet Clinical Need In Many Disease Areas
      • 11.2.3.6. Economic Growth In Emerging Market Provide Opportunity For Expansion
    • 11.2.4. Threats
      • 11.2.4.1. Intensifying Price Regulation In The Market
      • 11.2.4.2. Generic Competition - Likely Erosion Of Sales For Market Leading Brands
      • 11.2.4.3. Rising Costs Of R&D
      • 11.2.4.4. Biosimilars - A Potent Threat To Ophthalmic Drugs' Success
  • 11.3. Porter's Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
    • 11.3.1. Threat of New Entrants
    • 11.3.2. Rivalry Among Competitors
    • 11.3.3. Power of Suppliers
    • 11.3.4. Threat of Substitutes
    • 11.3.5. Power of Buyers

12. Expert Opinions from Our Primary Research

  • 12.1. Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate Communications & Investor Relations At ThromboGenics nv
    • 12.1.1. The Ophthalmic Drug Segments Presenting Growth Opportunities
    • 12.1.2. Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
    • 12.1.3. The Need To Embrace Novel Treatments
    • 12.1.4. Future Plans For Jetrea
    • 12.1.5. Expanding Treatment Indications And Strategies For Maximising Product Potential
    • 12.1.6. Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
    • 12.1.7. Development Efforts For Jetrea In Retinal Vein Occlusion
    • 12.1.8. Future Prospects For The Ophthalmic Drugs Market
  • 12.2. Interview With A Spokesperson From Akorn Pharmaceuticals
    • 12.2.1. New Formulation Strategies For Cosopt, Zioptan And Azasite
    • 12.2.2. Expansion Plans For Akorn's Ophthalmic Portfolio
    • 12.2.3. Tackling Key Unmet Needs Within Ophthalmics
    • 12.2.4. Akorn's Future Plans For Growth

13. Conclusions

  • 13.1. Overview Of Current Market Conditions And Market Forecast, 2014-2025
  • 13.2. Leading Sectors In Ophthalmic Drugs In 2014
  • 13.3. Leading Regions In The Ophthalmic Drugs Market In 2014
  • 13.4. Leading Companies In The Ophthalmic Drugs Market, 2014
  • 13.5. What Does The Future Hold For Ophthalmic Drugs?

List of Tables

  • Table 1.1: Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2014-2025 (Redacted Data)
  • Table 2.1: ICD 10 Classification of Visual Impairment, 2010
  • Table 2.2: Drug Treatments For Glaucoma, 2015
  • Table 2.3: Drug Treatments For Age-Related Macular Degeneration, 2015
  • Table 2.4: Drug Treatments For Ocular Allergy, 2015
  • Table 2.5: Drug Treatments For Ocular Inflammatory Disease, 2015
  • Table 2.6: Drug Treatments For Eye Infections, 2015
  • Table 2.7: Clinical Trial Phases, 2015
  • Table 3.1: The Global Ophthalmic Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2014
  • Table 3.2: The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2014-2025
  • Table 3.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2019, 2019-2025, 2014-2025
  • Table 3.4: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2014, 2019, 2025
  • Table 4.1: Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2014
  • Table 4.2: Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 4.3: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 4.4: Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.5: Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.6: Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.7: Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.8: Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 4.9: Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.1: Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2014
  • Table 5.2: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 5.3: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 5.4: Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.5: Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.6: Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.7: TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.8: Bromday: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.9: Cravit: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.10: Acular: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.11: AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 5.12: Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.1: Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 6.2: Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 6.3: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 6.4: Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.5: Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.6: Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.7: Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.8: Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.9: Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.10: Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.11: Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.12: Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 6.13: Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.1: Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 7.2: Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2014-2025
  • Table 7.3: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2014, 2019, 2025
  • Table 7.4: Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.5: Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.6: Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.7: Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.8: Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Table 7.9: Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.1: The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2014
  • Table 8.2: Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2014-2025
  • Table 8.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2019, 2019-2025, and 2014-2025
  • Table 8.4: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2014, 2019, and 2025
  • Table 8.5: The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.6: US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.7: The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2025
  • Table 8.8: The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2014
  • Table 8.9: The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.10: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2014, 2019, 2025
  • Table 8.11: The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.12: The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.13: The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.14: The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.15: The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.16: The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.17: The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.18: The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.19: The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.20: The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.21: The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.22: The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.23: The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.24: The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.25: The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.26: The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.27: The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.28: The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.29: The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.30: The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.31: The Mexican Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.32: The Mexican Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 8.33: The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2014-2025
  • Table 8.34: The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.1: Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2014
  • Table 9.2: Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2014-2025
  • Table 9.3: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2014, 2019, 2025
  • Table 9.4: Novartis: Company Overview, 2015
  • Table 9.5: Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.6: Allergan: Company Overview, 2015
  • Table 9.7: Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.8: Roche: Company Overview, 2015
  • Table 9.9: Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.10: Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.11: Santen: Company Overview, 2015
  • Table 9.12: Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.13: Regeneron: Company Overview, 2015
  • Table 9.14: Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.15: Valeant: Company Overview, 2015
  • Table 9.16: Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.17: Pfizer: Company Overview, 2015
  • Table 9.18: Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.19: Bayer: Company Overview, 2015
  • Table 9.20: Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 9.21: Senju: Company Overview, 2015
  • Table 9.22: Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 10.1: Retinal Disorders Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.2: Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.3: Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 10.4: Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.5: Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.6: Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 10.7: Glaucoma Drugs Pipeline: Phase 2&3 Drugs, 2015
  • Table 10.8: Glaucoma Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2015
  • Table 10.9: Dry Eye Drugs Pipeline: Phase 3 Drugs, 2015
  • Table 10.10: Dry Eye Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.11: Other Pipeline Products for Ophthalmic Conditions, 2015
  • Table 11.1: SWOT Analysis of the Global Ophthalmic Drugs Market, 2015-2025
  • Table 11.2: World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
  • Table 11.3: Global Prevalence Forecast for Ophthalmic Diseases from 2014
  • Table 13.1: Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2014, 2018, 2021, 2025
  • Table 13.2: The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2014, 2018, 2021, 2025

List of Figures

  • Figure 1.1: Global Ophthalmic Drugs Market: Market Sectors, 2015
  • Figure 1.2: Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%) 2014-2025 (Altered Data)
  • Figure 2.1: Structure Of The Human Eye
  • Figure 2.2: Estimated Global Prevalence Of Visual Impairment (millions of people), 2014
  • Figure 2.3: Global Causes of Visual Impairment (% of cases), 2012
  • Figure 2.4: Classification Of Glaucoma, 2015
  • Figure 3.1: The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2014
  • Figure 3.2: The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 3.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2019
  • Figure 3.4: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2019-2025
  • Figure 3.5: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2014-2025
  • Figure 3.6: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2014
  • Figure 3.7: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2019
  • Figure 3.8: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2025
  • Figure 4.1: Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m), 2014
  • Figure 4.2: Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 4.3: Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2014-2025
  • Figure 4.4: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 4.5: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 4.6: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 4.7: Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.8: Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.9: Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.10: Visudyne: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.11: Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2014-2025
  • Figure 4.12: Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.1: Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2014
  • Figure 5.2: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 5.3: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
  • Figure 5.4: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 5.5: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 5.6: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 5.7: Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.8: Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.9: Vigamox: Novartis Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.10: TobraDex: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.11: Bromday: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.12: Cravit: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.13: Acular: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.14: AzaSite: Akorn Sales Forecast ($m, AGR%), 2014-2025
  • Figure 5.15: Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.1: Leading Glaucoma Drugs: Revenue ($m), 2014
  • Figure 6.2: Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 6.3: Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
  • Figure 6.4: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 6.5: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 6.6: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 6.7: Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.8: Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.9: Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.10: Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.11: Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.12: Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.13: Azopt: Novartis Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.14: Tapros: Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.15: Zioptan: Akorn Sales Forecast ($m, AGR%), 2014-2025
  • Figure 6.16: Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.1: Leading Dry Eye Drugs: Revenue ($m), 2014
  • Figure 7.2: Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 7.3: Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
  • Figure 7.4: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2014
  • Figure 7.5: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2019
  • Figure 7.6: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2025
  • Figure 7.7: Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.8: Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.9: Hyalein: Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.10: Diquas: Santen Sales Forecast ($m, AGR%), 2014-2025
  • Figure 7.11: Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Figure 7.12: Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2014-2025
  • Figure 8.1: The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2014
  • Figure 8.2: US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.3: Brazil, Russia, India, and Mexico Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.4: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2019
  • Figure 8.5: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2019-2025
  • Figure 8.6: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2014-2025
  • Figure 8.7: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2014
  • Figure 8.8: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2019
  • Figure 8.9: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2025
  • Figure 8.10: US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.11: The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2014
  • Figure 8.12: Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2014-2025
  • Figure 8.13: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2014
  • Figure 8.14: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2019
  • Figure 8.15: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2025
  • Figure 8.16: The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.17: The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.18: The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.19: The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.20: The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.21: The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.22: The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.23: The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.24: The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.25: The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.26: The Mexican Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 8.27: The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 9.1: Leading Ophthalmic Drug Companies: Revenue ($m), 2014
  • Figure 9.2: Ophthalmic Drugs Market: Market Forecast ($m, AGR%) by Leading Companies, 2014-2025
  • Figure 9.3: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2014
  • Figure 9.4: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2019
  • Figure 9.5: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2025
  • Figure 9.6: Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.7: Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.8: Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.9: Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.10: Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.11: Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.12: Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.13: Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.14: Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 9.15: Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2014-2025
  • Figure 11.1: World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
  • Figure 11.2: Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
  • Figure 11.3: Porter's Five Force Analysis of the Ophthalmic Drugs Market, 2015
  • Figure 13.1: Global Ophthalmic Drugs: Market Forecast ($m), 2014, 2018, 2021, 2025
  • Figure 13.2: The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2014-2025

Companies Listed

  • Abbott
  • Actavis
  • Acucela
  • Advanced Cell Technologies
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Akorn Pharmaceuticals
  • Alcon (Novartis)
  • Aldeyra Therapeutics
  • Alimera Sciences
  • Allegro Ophthalmics
  • Allergan
  • Amakem
  • Amgen
  • Ampio Pharmaceuticals
  • AstraZeneca
  • Banyu Pharmaceutical
  • Barr Laboratories
  • Bausch and Lomb
  • Bayer
  • Bicycle Therapeutics
  • Biocad
  • BioDem
  • Biovail Corporation (Valeant)
  • BioXpress Therapeutics
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Chengdu Kanghong Pharmaceutical
  • Colby Pharmaceutical
  • Daiichi Sankyo
  • Delenex Therapeutics
  • Eleven Biotherapeutics
  • ESBA Tech
  • EyeCyte
  • EyeGate
  • Eyetech Pharmaceuticals
  • ForSight Biotherapeutics
  • Genaera Corporation
  • Gene Signal
  • Genentech (Roche)
  • GlaxoSmithKline
  • High-Tech Pharmacal
  • Hospira (Pfizer)
  • iCo Therapeutics
  • Icon Bioscience
  • InSite Vision
  • Inspire Pharmaceuticals (Merck)
  • Instituto Terapeutico Delta Ltda (Valeant)
  • ISTA Pharmaceuticals
  • Johnson & Johnson
  • Kala Pharmaceuticals
  • KalVista
  • Kestrel Ophthalmics
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MAP Pharmaceuticals
  • Meda Pharmaceuticals
  • Merck & Co
  • MerLion Pharma
  • Mimetogen Pharma
  • Molecular Partners AG
  • Morgan Stanley
  • Mystic Pharmaceuticals
  • Neurim Pharmaceuticals
  • Neurotech
  • NovaBay
  • Novartis
  • OcuSciences
  • OHR Pharmaceutical
  • Omeros
  • Oncobiologics
  • OphthaliX
  • Ophthotech
  • Othera Pharmaceuticals
  • Oxigene
  • Pan Optica
  • Patheon Pharmaceuticals
  • Pershing Square Capital
  • Pfizer
  • Premacure (Shire)
  • Procter & Gamble
  • pSivida
  • QLT
  • Quark Pharmaceuticals
  • Reckitt Benckiser
  • Regeneron
  • Roche
  • R-Tech Ueno
  • Salix Pharmaceuticals (Valeant)
  • Sandoz (Novartis)
  • Santen
  • SARcode Bioscience
  • Seikagaku
  • Senju
  • Servier
  • Shire
  • Sirna Therapeutics
  • Spark Therapeutics
  • Swedish Orphan Biovitrium AB (Sobi)
  • Symphony VIDA
  • Takeda
  • The Patent Board
  • ThromboGenics
  • Valeant
  • Vanda Pharmaceuticals
  • Warburg Pincus LLC
  • Wockhardt
  • Zhejiang Huahai Pharmaceutical

Organisations Mentioned In The Report

  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Department of Pharmaceuticals [India]
  • Emory University, Georgia, US
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA) [US]
  • Foundation Fighting Blindness (FFB)
  • Institute of Experimental Medicine, St Petersburg, Russia
  • International Diabetes Federation
  • Italian Competition Authority
  • Italian Medicines Agency (AIFA)
  • Japan Patent Office
  • Memorial Sloan Kettering Cancer Center, New York, US
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Monash University, Australia
  • National Development and Reform Commission [China]
  • National Eye Institute [US]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Pharmaceutical Pricing Authority (NPPA) [India]
  • Novartis Institutes for Biomedical Research (NIBR)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Portsmouth Primary Care Trust [UK]
  • Southampton Primary Care Trust [UK]
  • Tokyo University of Science
  • United Nations' Department of Economic and Social Affairs
  • University of Florida, US
  • University of Melbourne, Australia
  • US Patent and Trademark Office
  • US Preventive Services Task Force (UPSTF)
  • World Bank
  • World Health Organisation (WHO)
Back to Top